Browsing: SUSTAIN 1

In patients with type 2 diabetes inadequately managed by diet and exercise alone, once-weekly semaglutide monotherapy significantly reduced HbA1c and body weight compared to placebo, demonstrating a promising safety profile, though with mild-to-moderate gastrointestinal side effects.